STAT2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
FierceBiotech1d
Hidden data on obesity prospect wipe $12B off Amgen market cap
The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 ...
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone ...
STAT4h
AbbVie’s stumble, Amgen’s tumble and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Amgen Sees No Bone Safety Concerns Around Experimental Obesity Drug
(Reuters) - Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, ...